PNAS:饮用含砷水或刺激对利什曼病药物的耐药性

2013-10-30 伊文 EurekAlert中文

一项研究报告说,饮用水的砷污染可能促进一种致命的寄生虫病的广泛存在的耐药性。内脏利什曼病每年导致4.1万人死亡。只有4种药物——锑制剂、两性霉素B、米替福新和巴龙霉素——已知能够杀死在病人的脾脏、肝脏和骨髓细胞中繁殖的利什曼原虫。【原文下载】 Alan H. Fairlamb及其同事探索了一种可能性,即长期暴露在饮用水的砷污染中可能促进感染利什曼原虫的病人对含有锑的药

一项研究报告说,饮用水砷污染可能促进一种致命的寄生虫病的广泛存在的耐药性。内脏利什曼病每年导致4.1万人死亡。只有4种药物——锑制剂、两性霉素B、米替福新和巴龙霉素——已知能够杀死在病人的脾脏、肝脏和骨髓细胞中繁殖的利什曼原虫。【原文下载】

Alan H. Fairlamb及其同事探索了一种可能性,即长期暴露在饮用水的砷污染中可能促进感染利什曼原虫的病人对含有锑的药物的交叉耐性。这组作者让小鼠接触含有环境相关浓度的砷的饮用水,直到这些啮齿动物的器官和其他组织达到了类似于报道的接触砷的人类的砷浓度。

这组作者然后用杜氏利什曼原虫(Leishmania donovani)感染了这些小鼠,在1到2个月之后提取了这些寄生虫,然后把得到的寄生虫通过后来的接触砷的小鼠组传下去,一共进行了5个月时间。对最后一个小鼠组的实验表明,这些利什曼原虫出现了对锑药物葡萄糖酸锑的完全而稳定的耐性。这组作者说,这项研究提示饮用水的砷污染可能在利什曼原虫锑药物的耐药性发展方面起到了一个重要作用。

原文出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1855451, encodeId=150f1855451ef, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jun 06 10:04:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951231, encodeId=65a119512315a, content=<a href='/topic/show?id=4f5c322640f' target=_blank style='color:#2F92EE;'>#利什曼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32264, encryptionId=4f5c322640f, topicName=利什曼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Jun 29 05:04:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595954, encodeId=b96815959549a, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Nov 01 04:04:00 CST 2013, time=2013-11-01, status=1, ipAttribution=)]
    2014-06-06 医者仁心
  2. [GetPortalCommentsPageByObjectIdResponse(id=1855451, encodeId=150f1855451ef, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jun 06 10:04:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951231, encodeId=65a119512315a, content=<a href='/topic/show?id=4f5c322640f' target=_blank style='color:#2F92EE;'>#利什曼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32264, encryptionId=4f5c322640f, topicName=利什曼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Jun 29 05:04:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595954, encodeId=b96815959549a, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Nov 01 04:04:00 CST 2013, time=2013-11-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1855451, encodeId=150f1855451ef, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jun 06 10:04:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951231, encodeId=65a119512315a, content=<a href='/topic/show?id=4f5c322640f' target=_blank style='color:#2F92EE;'>#利什曼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32264, encryptionId=4f5c322640f, topicName=利什曼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Jun 29 05:04:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595954, encodeId=b96815959549a, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Nov 01 04:04:00 CST 2013, time=2013-11-01, status=1, ipAttribution=)]
    2013-11-01 仁医06